Literature DB >> 23390167

Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.

Miriam Englander1, Teresa C Chen, Eleftherios I Paschalis, Joan W Miller, Ivana K Kim.   

Abstract

AIM: To report the incidence rate of acute postoperative endophthalmitis secondary to therapeutic intravitreal injections.
METHODS: A retrospective review of all consecutive eyes after intravitreal injections was performed at the Massachusetts Eye and Ear Infirmary, Boston, from 1 January 2007 to 31 December 2011.
RESULTS: During the 5-year study interval, 10 208 intravitreal injections were performed. The overall incidence rate of endophthalmitis was 0.029% per injection (3 of 10 208 injections). In the three cases, in our series, the endophthalmitis occurred at an average of seven injections, which lies within the SD of the mean number of injections received by each eye in this study, suggesting approximately equal probability of infection for each eye after receiving multiple, sequential injections. Bacterial cultures and Gram stain revealed coagulase-negative Staphylococcus species (n=1), moderate bacteria with negative culture (n=1) and moderate Staphylococcus epidermidis (n=1). All cases were successfully treated using either intravitreal antibiotics and steroids or pars plana vitrectomy. Best-corrected visual acuity reduction was not clinically significant at the last visit (>7 months for all cases).
CONCLUSIONS: Acute endophthalmitis is a rare potential complication after intravitreal injection. Further studies are required to elucidate the best prophylactic and aseptic techniques to prevent this rare complication.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23390167     DOI: 10.1136/bjophthalmol-2012-302435

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  20 in total

Review 1.  Prevention and treatment of injection-related endophthalmitis.

Authors:  Charles Q Yu; Christopher N Ta
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-08       Impact factor: 3.117

2.  Postoperative endophthalmitis incidence after intravitreal therapy: a comparison of two different preoperative antibiotic prophylaxis.

Authors:  Sergio Piscitello; Maria Vadalà
Journal:  Int Ophthalmol       Date:  2016-09-01       Impact factor: 2.031

3.  The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease.

Authors:  Richard L Sidman; Jianxue Li; Matthew Lawrence; Wenzheng Hu; Gary F Musso; Ricardo J Giordano; Marina Cardó-Vila; Renata Pasqualini; Wadih Arap
Journal:  Sci Transl Med       Date:  2015-10-14       Impact factor: 17.956

4.  Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor-β/δ.

Authors:  Sandra Suarez; Gary W McCollum; Colin A Bretz; Rong Yang; Megan E Capozzi; John S Penn
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-18       Impact factor: 4.799

Review 5.  Nanotechnology in retinal drug delivery.

Authors:  Sibo Jiang; Yesenia L Franco; Yan Zhou; Jianjun Chen
Journal:  Int J Ophthalmol       Date:  2018-06-18       Impact factor: 1.779

6.  Culture-Proven Endophthalmitis After Intravitreal Injection: A 10-Year Analysis.

Authors:  Joseph M Simonett; Austin Igelman; Stanford C Taylor; J Peter Campbell; Thomas S Hwang; Phoebe Lin; Andreas K Lauer; Christina J Flaxel
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2019-01-01       Impact factor: 1.300

7.  Burkholderia cepacia endophthalmitis, in a penicillin allergic patient, following a ranibizumab injection.

Authors:  Norman Saffra; Emily Moriarty
Journal:  BMJ Case Rep       Date:  2014-02-13

8.  Current and future management of diabetic retinopathy: a personalized evidence-based approach.

Authors:  Ryan J Fante; Thomas W Gardner; Jeffrey M Sundstrom
Journal:  Diabetes Manag (Lond)       Date:  2013-11-01

9.  Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.

Authors:  Stephen G Schwartz; Harry W Flynn
Journal:  Curr Ophthalmol Rep       Date:  2014-03-01

Review 10.  Ocular Infection: Endophthalmitis.

Authors:  Stephen G Schwartz; Harry W Flynn; Taraprasad Das; William F Mieler
Journal:  Dev Ophthalmol       Date:  2015-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.